Preclinical safety profile of sildenafil

International Journal of Impotence Research

Volumn 16, Issue 6, 2004, Pages 498-504

  Abbott, D ^a   Comby, P ^a   Charuel, C ^a   Graepel, P ^b   Hanton, G ^a   Leblanc, B ^a   Lodola, A ^a   Longeart, L ^a   Paulus, G ^b   Peters, C ^a   Stadler, J ^a  

^a PFIZER INC   (United States)

^b Pfizer ^*

Author keywords

Erectile dysfunction; Safety; Sildenafil; Toxicology; Viagra

Indexed keywords

SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENIC ACTIVITY; CONTROLLED STUDY; DOG; DRUG MARKETING; DRUG SAFETY; ERECTILE DYSFUNCTION; GENOTOXICITY; GOITER; LIVER HYPERTROPHY; MORPHOMETRICS; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; RETINA; SPECIES DIFFERENCE; VISUAL DISORDER;

EID: 10844291659     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901232     Document Type: Article

References (21)

1. USFDA. Center for Drug Evaluation and Research Application Number NDA 20-895 Pharmacology Reviews.
2. CPMP/1136/98 rev 2 Scientific Discussion ©EMEA. 2000.
3. ICH: Guidance on Non-Clinical Safety Evaluation.
4. Nicholson CD, Challiss RAJ, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TiPS 1991; 12: 19-27.
5. Geelen P et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000; 102: 275-277.
6. Zusman RM, Morales A, Classer DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cordial 1999; 83: 35C-44C.
7. Comer CP, Chengelis CP, Levin S, Kotsoris FN. Changes in thyroidal function and liver UDP glucurosyl transferase activity in rats following administration of a novel imidazole (SC-37211). Toxicol Appl Pharmacol 1985; 80: 427-436.
8. Lumb GD, Rust JH. The pathologic response of the liver and thyroid of the rat to potassium prorenoate (SC-23992). Toxicol Pathol 1985; 13: 315-324.
9. Hill RN et al. Thyroid follicular cell carcinogenesis. Fundam Appl Toxicol 1989; 12: 629-697.
10. McClain RM, Posch RC, Bosakowski T, Armstrong JM. Studies on the mode of action for thyroid gland tumour promotion in rats by phenobarbital. Toxicol Appl Pharmacol 1988; 94: 254-265.
11. McClain RM. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia. Toxicol Pathol 1989; 17: 294-306.
12. Johnson S, McKillop D, Miller J, Smith IK. The effects on rat thyroid function of a hepatic microsomal enzyme inducer. Hum Exp Toxicol 1993; 12: 153-158.
13. Davies DT. Assessment of rodent thyroid endocrinology: advantages and pit-falls. Comp Haematol Int 1993; 3: 142-152.
14. Hayes TJ, Roberts GKS, Halliwell WH. An idiopathic febrile necrotizing arteritis syndrome in the dog: beagle pain syndrome. Toxicol Pathol 1989; 17: 129-137.
15. Snyder PW et al. Pathologic features of naturally occurring juvenile polyarteritis in Beagle dogs. Vet Pathol 1995; 32: 337-345.
16. Stejskal V, Havu N, Malmfors T. Necrotizing vasculitis as an immunological complication in toxicity study. New Toxicology for Old. Arch Toxicol 1982; (Suppl 5): 283-286.
17. Ruben Z et al. Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: a possible genetic predilection. Toxicol Pathol 1989; 17: 145-152.
18. Schlaeppi B, Roncari G, Zahm P. Vascular toxicity in dogs associated with overdoses of a novel benzodiazepine receptor partial agonist. Arch Toxicol 1991; 65: 73-80.
19. Detweiler DK. Spontaneous and induced arterial disease in the dog: pathology and pathogenesis. Toxicol Pathol 1989; 17: 94-108.
20. Kerns WD, Roth L, Hosokawa S. Idiopathic canine polyarteritis. In: Mohr U, Carlton WW, Dungworth DL, Benjamin SA, Capen CC, Hahn FF (eds). Pathobiology of the Aging Dog, 1st edn, Vol. 2. Iowa State University Press: Ames, 2000, pp 118-126.
21. Wong CL, Roberts MB, Wai MK. Effect of morphine and naloxone on intestinal transit in mice. Eur J Pharmacol 1980; 64: 289-295.